Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If you have done what you were posting than this could make you some extra money.
If we drop below $11 I'll be buying some extra shares myself.
Some websites still have the data on Jiangbo mixed up, look at this one. Yeah right: 24M shares outstanding, eps -$0.45 Sure ?!
Time the company or the IR firm straightened this out.
I think I am going to sell.
I think 5% but don't know for sure
I think these numbers follow from SEC filings. So as long as you're not named in a SEC-filing from JGBO, or you yourself do not have to file with SEC, your name will not show up.
I guess you told the nitwit to sell?
A few months ago (30th Sept 09) Ardsley didn't have any shares JGBO at all, see here
That makes me certain they have recently converted some warrants or debt. Total worth of 231,251 X $8 = $ 1,850,008
I think we have no more shares of LTUS and we still hold 6+M shares in GHII, see these links:
- ownership GHII
- ownership LTUS
If we look at the ownerships of shres Jiangbo, it looks like Ardsley has converted debt and/or excersised some warrants?
See here
If you look at the list with other holders at the bottom of the page you'll see some incrowd holding shares. It is funny to think that some of the longs here own more shares than the insiders.
So now outstanding shares are about 12 million I guess. We'll know for sure when the next earnings release is out, expect that in 4-5 weeks. Hopefully we'll uplist first!
That's what I like to hear! We all here know that it is just like that, now let's see if the market and institutional) investors will too. This year should become an exciting year for us longs!
Congratulations _bbb_, I hope I can buy you some lekkerbekjes soon!
How does it feel to be 37 (that's so I can prepare myself, cause it's going to happen to me within a few months too),
The new certificate:
donwload it yourself
A few weeks ago JGBO shares traded around $10. At that time I thought that if we had green light on the Nasdaq listing, the pps might rise to let's say $20. Since then the pps has risen to today's level of $14.
If the news on Nasdaq where to come out today we surely would gain the same $10, then we would have a pps of $24. Or would it double from $14 to $28? Or would the pps gain $6 or so?
What do you guys think? Will the news on uplisting result in an A absolute rise (of $10 for example) or B relative rise (like say a doubling in shareprice) or C will it bring us to a fixed level, let's say a shareprice of $20?
This must mean something good! More sales, more revenues, more profit!
Jiangbo Pharmaceuticals' Osteomyelitis Treatment Tablets to be Included in China's National Insurance Directory
LAIYANG, China, Jan. 13 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) (the "Company" or "Jiangbo"), a pharmaceutical company with its principal operations in China, today announced that its Osteomyelitis treatment tablets (Kang Gu Sui Yan Pian) has been included in the 2009 Edition of the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Medicine Directory ("the Directory").
Jiangbo is the exclusive manufacturer of Osteomyelitis treatment tablets in China. This product is used to treat bone and bone marrow inflammations. It's a 100% herb-based traditional Chinese medicine. Most osteomyelitis patients currently use chemical drugs such as antibiotics for treatment which may develop drug resistance if the chemical drugs are taken over a long period of time. Chronic patients are also likely to need surgery which is a less preferable treatment for patients in China. Jiangbo's Osteomyelitis treatment tablets offer an alternative mild treatment and were clinically tested to be effective in treating long term osteomyelitis problems.
The Company has four other products which have been included in the Directory. They are Radix Isatidis Granules, Motherwort Herb Electuary (Yi Mu Cao Gao), Ciprofloxacin Hydrochloride tablets and Paracetamol tablets. Currently, the Company is producing limited quantities of these four products.
"The inclusion of Osteomyelitis treatment tablets in the 2009 Edition Directory is an important accomplishment for our Company," said Mr. Wubo Cao, the Company's Chief Executive Officer. "As its exclusive manufacture, we expect the inclusion of Osteomyelitis treatment tablets in the Directory to drive meaningful sales volume growth in future."
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website ( http://www.jiangbopharma.com ).
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, anticipated sales volume growth of the medicines, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
For more information, please contact:
Jiangbo Pharmaceuticals, Inc.
Ms. Elsa Sung, CFO
Phone: +1-954-727-8435
Email: elsasung@jiangbo.com
Web: http://www.jiangbopharma.com
CCG Investor Relations, Inc.
Mr. Crocker Coulson, President
Phone: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Web: http://www.ccgirasia.com
SOURCE Jiangbo Pharmaceuticals, Inc.
-0- 01/13/2010
/CONTACT: Ms. Elsa Sung, CFO of Jiangbo Pharmaceuticals, Inc.,
+1-954-727-8435, elsasung@jiangbo.com; Investor Relations Contact: Crocker Coulson, President of CCG Investor Relations, crocker.coulson@ccgir.com,
+1-646-213-1915 (NY office) /
/Web site: http://www.jiangbopharma.com/
(JGBO JGBO.OB)
Dec 31st short interest was 37k shares. Fourteen days before that it was 39k. Maybe last weeks climb was caused by the shorts wanting to buy back?
On the other hand: volume has been way better than 37k shares. So best guess is that this climb is more/better than shorts getting covered!
Looke here under the tab "Short Interest"
I have found similar numbers, but you can see they once owned about 6.7M shares?
See here
or
Look at this page
Then they sold 680k shares and gave away another 657k shares as s bonus. That still leaves another 6M shares unexplained but I think you are right in explaining why we can't find any proof of that. I once asked a question in an e-mail to Mr. Coulson about the Lotus shares, he never answered this specific question. We can only gues.
Most likely they were sold and proceeds used to pay bills for legal advice/lawsuits etc. Just after the merger it was promised these assets (shares in LTUS and SPEH now GHII) would be sold and dividended out to the pre-merger US-shareholders. This never happened (unfortunately because I am a pre-merger shareholder)...
I do know we still hold shares in GHII: look here
I think it is safe to assume we don't have any share LTUS anymore.
Not the big news we were waiting for. But nevertheless it is GOOD news:
LAIYANG, China, Jan. 12 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) (the "Company" or "Jiangbo"), a pharmaceutical company with its principal operations in China, today announced that one of its factories in China obtained a renewal of its Good Manufacturing Practices Certificate for Pharmaceutical Products ("GMP Certificate") from the State Food and Drug Administration (SFDA) for its tablets and granules. The new certificate will be valid until November 2014. Jiangbo has another GMP certified factory to produce Traditional Chinese medicines in tablets, granules, pills, mixture, syrup, and concentrated decoction.
According to the National Medicine Administration Law of the People's Republic of China, all pharmaceutical manufacturers are required to pass an examination every five years to renew their GMP Certificates. In November 2009, the examination committee visited the Company and conducted a review of its supply chain management practices, including quality control of raw materials, its manufacturing processes, and the inspection and acceptance of its finished products.
"We are pleased to obtain the renewal of our GMP Certificate, which reinforces Jiangbo's commitment to providing the highest quality pharmaceutical products to patients," said Mr. Wubo Cao, the Company's Chief Executive Officer.
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website (http://www.jiangbopharma.com ).
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
For further information, please contact:
Jiangbo Pharmaceuticals, Inc.
Ms. Elsa Sung, CFO
Phone: +1-954-727-8435
Email: elsasung@jiangbo.com
Web: http://www.jiangbopharma.com
CCG Investor Relations, Inc.
Mr. Crocker Coulson, President
Phone: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Web: http://www.ccgirasia.com
I really can't be of more help: I don't think they still own these shares because I can't find any proof. But I can't find any document that states they have sold their shares of LTUS either...
They once held several millions of shares in Lotus, if they still own some it is far less than that number I think. I remember they had to give some shares away because of a settlement ?!
Conclusion: we have had a nice week. With a cool down on friday, or shall we say consolidation on a higher level?
I am satisfied, some more of these weeks and we're golden!
Shocking news?
No, read it yourself, "change" in accounting firm
Bigplay: the usual quarterly results have always been reported within approx. 6 weeks after the end of the quarter. Numbers on a fiscal year are reported 10 weeks after the year's end.
I don't think becoming an accelerated filer makes much of a difference? See here:
link to sec website
Seems like we've found the right track again...
Off day?
Maybe someone found out that Q2 brought great revenues, or that uplisting is around the corner, or that they have bought a fantastic new drug, or that one of the three drugs in the pipeline has been approved and is now ready for production, or institutional investors picking up...
So you see today's run could be caused by a lot of things
When I look at level2 I can't find NITE anymore? Where they absent the whole day? Is that why we have started a nice climb?
Let's just say that I am a firm believer...
I have been waiting for 2 years now, so a few weeks extra won't hurt me
Nice to see volume picking up from time to time, so we know we're not falling into oblivion. Good to have confirmation every now and then...
Good start. Nice volume, but not unusual around the end of a fiscal quarter. Spikes in volume occur often around JGBO's quarter-ends.
Uplisting hopefully on its way...
I wish you guys here all the best for 2010! Happy new year
...and that for two days in a row, who can imagine what tomorrow will bring, or next week, or even next month
GLTA
That would be nice after the past period of consolidation. What is good to see that we had nice volume today and that most shares where sold at $10.70, so it's not just a painted close.
Well those deals (Nov. 2007 and May 2008) still bother me too. I don't know for 100% sure if their good or bad. I just think a price per share of $30-40 is still very possible... IF Jiangbo gets listed on the Nasdaq.
Now something positive.
From yahoo-board:
"The metric that the street will look at , once this deal is uplisted is free cash flow from operations, which is basically earnings + non cash charges. A pharma should trade AT LEAST 12x FREE CASH FLOW, PLUS the amount of Net Equity.
The Free Cash flow is about $40,000,000 per year, and cash on hand/net equity after the conversion is 130,000,000 or so.
Figure that the conversion would yeild 16 million shares, total, fully diluted.
$40,000,000 x 12 = 500,000,000 Plus 130,000,000 equity, should yeild a $630,000,000 market cap./ 16,000,000 fully diluted shares and the price projection, or Valuation for where the company is NOW is $39.37....
Start accumualting.... it is just a matter of time... "
Thanks pegleg-melon-rind, whoever you are!
Here is the link to the original post.
Form the filing concerning the deal with Pope:
The Debenture may not be prepaid without the prior written consent of the Holder.
Hmm, don't know what to think of your theory. My best guess is that the shares Pope holds are not restricted, they have sold some before. The filing you copy/paste from states that Pope holds 1.14 Million shares, see page 4.
They know hold many less shares, I believe 82,500
look here Of course that number has changed since it is a few months old...
Short-interest went up last weeks:
Dec 15, 2009: 39,187
Higher volumes last days because these had to be covered? Or do shorters know more than we do ... ?
A bit early:
Merry christmas everybody!
Maybe these shares are the reason why we are seeing fairly high volumes:
Note 19- Subsequent events
In October 2009, the Company issued 462,500 shares of its common stock in connection with the conversion of $3,700,000 of May 2008
Convertible Debentures.
We'll know for sure after the next filing, outstanding number will be updated after that.
BigGreen101: I cannot answers all your questions yet. I'll start with the last issue you point ut. I think they hired KPMG a 1~2 years or more ago to help them get SOX 4040 compliant. I think the segregation of duties could be necessary for SOX 404 compliancy. I don't know if compliancy has to be a fact to get uplisted. I cannot recal a PR of them hiring a firm to get uplisted.
I think a part of the money (5 Million) went into an agreement with a university. The money was meant to help make LFAA ready for approval and production. Should try to find a PR on that...(this is just as far as I can remember)
Update:
On November 8, 2007, the Company announced completion of a private placement for $5.0 million with Pope Investments, LLC. The
Company plans to use most of the net proceeds from this transaction to purchase the patent for the drug Ligustrazine Ferulic Acid Acetate, one
of the Company’s drugs currently in phase III clinical trial.
See page 6: of this file
The rest of the money went into their cash position I guess? Doesn't seem logical I know...
Maybe someone else can help us out with these questions. (Have you mailed Crocker or Elsa ?)